Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients
Treatment with Cosentyx (secukinumab) reduced fatigue for up to three years in people with active ankylosing spondylitis (AS), particularly those who had never received TNF inhibitors, according to two Phase 3 clinical trials. Age and…